Independent Biopharmaceutical Company Specialised Therapeutics Asia Pte Ltd (St) Will Partner With Cttq-Akeso (Shanghai) Biomed. Tech. Co., Ltd. (Cttq-Akeso) (Jointly Established By Akeso, Inc. And Chia Tai Tianqing Pharmaceutical Group Co., Ltd.)To Commercialise A New Immuno-Oncology Therapy In Australia, Singapore And Across Southeast Asia.The Therapy Anniko (Penpulimab) Is An Anti-Pd1 Monoclonal Antibody Currently Under Regulatory Review By The Us Fda For Nasopharyngeal Carcinoma
